Advertisement
Canada markets open in 9 hours 25 minutes

  • S&P/TSX

    21,885.38
    +11.66 (+0.05%)
     

  • S&P 500

    5,048.42
    -23.21 (-0.46%)
     

  • DOW

    38,085.80
    -375.12 (-0.98%)
     

  • CAD/USD

    0.7322
    -0.0001 (-0.01%)
     

  • CRUDE OIL

    83.82
    +0.25 (+0.30%)
     

  • Bitcoin CAD

    87,885.23
    +52.84 (+0.06%)
     

  • CMC Crypto 200

    1,390.06
    +7.48 (+0.54%)
     

  • GOLD FUTURES

    2,346.40
    +3.90 (+0.17%)
     

  • RUSSELL 2000

    1,981.12
    -14.31 (-0.72%)
     

  • 10-Yr Bond

    4.7060
    +0.0540 (+1.16%)
     

  • NASDAQ futures

    17,767.75
    +200.25 (+1.14%)
     

  • VOLATILITY

    15.37
    -0.60 (-3.76%)
     

  • FTSE

    8,078.86
    +38.48 (+0.48%)
     

  • NIKKEI 225

    37,929.26
    +300.78 (+0.80%)
     

  • CAD/EUR

    0.6826
    +0.0005 (+0.07%)
     

COVID vaccines: Novavax says India, Europe, South Korea to supply global doses for 2022

Anjalee Khemlani
·Senior Reporter
Updated ·2 min read

Novavax (NVAX) is awaiting the outcome of a June 7 meeting of the FDA's vaccine advisory committee, which could finally bring its COVID-19 vaccine to the U.S. market.

Chief Commercial Officer John Trizzino told Yahoo Finance in an exclusive interview Wednesday that the company is optimistic about the upcoming meeting.

Novavax ran into manufacturing quality problems in early 2021 and experienced subsequent delays in its Phase 3 trial in the U.S., forcing the company to push back its timeline from mid-2021 to what could now be mid-2022.

To resolve its manufacturing crisis, it turned to the world's largest vaccine maker, the Serum Institute of India (SII). That manufacturer was also in hot water in early 2021. SII was supposed to provide the bulk of the world's vaccines through the global COVAX facility partnership by producing AstraZeneca (AZN)/Oxford's COVID-19 vaccine. A deadly Delta wave caused India to implement an export ban, reserving doses for domestic distribution along with those of another local vaccine company.

ADVERTISEMENT

Last year, Novavax CEO Stanley Erck made trips to SII in Pune, in the state of Maharashtra, to work out the deal that would eventually move Novavax's vaccine forward.

Trizzino said the FDA has now completed inspection at the Serum Institute, and the doses for the U.S. market, at least initially, will be coming from India.

"They've built out capacity for us over the last couple of years," Trizzino said of SII.

Doses from that facility have been sent to Europe, where Novavax also has a manufacturing site in the Czech Republic, as well as to Australia and Canada. For 2022, South Korea's SK bioscience and the Czech site will be the manufacturing sources, along with Serum, Trizzino said.

Novavax has said it is eyeing the vaccine hesitant, especially those who are wary of the newer mRNA technology, such as Pfizer (PFE)/BioNTech (BNTX) and Moderna (MRNA), or of the rare side effects associated with adenovirus vaccines like AstraZeneca and Johnson & Johnson (JNJ).

What the FDA and CDC decide about the two-dose recombinant protein vaccine will determine the company's fate for the year.

"I think we're now in a position to have a successful '22," Trizzino said, noting the year will be foundational for the company.

"We believe we are going to have sustainable revenue generation and be an important part of annual revaccination for COVID for the foreseeable future," he added.

Follow Anjalee on Twitter @AnjKhem

Read the latest financial and business news from Yahoo Finance

Follow Yahoo Finance on Twitter, Instagram, YouTube, Facebook, Flipboard, and LinkedIn